Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New pill combo aims to fight back against tough lung cancer

NCT ID NCT03672773

Summary

This study is testing whether taking two oral drugs together works better than either alone for people with a fast-growing type of lung cancer that has returned after initial chemotherapy. The drugs, talazoparib and temozolomide, aim to stop cancer cells from growing by damaging their DNA and preventing repair. The goal is to see if this combination can shrink tumors and control the disease for people with limited treatment options.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT EXTENSIVE STAGE SMALL CELL LUNG CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • CBCC Global Research, Inc. at Comprehensive Blood and Cancer Center

    Bakersfield, California, 93309, United States

  • Cancer Center of Kansas

    Wichita, Kansas, 67214, United States

  • Ft. Wayne Medical Oncology and Hematology, Inc.

    Fort Wayne, Indiana, 46804, United States

  • Orlando Health, Inc. d/b/a Orlando Health UF Health Center

    Orlando, Florida, 32806, United States

  • St. Joseph Heritage Healthcare

    Fullerton, California, 92835, United States

  • UCLA / Jonsson Comprehensive Cancer Center

    Los Angeles, California, 90095, United States

Conditions

Explore the condition pages connected to this study.